je.st
news
Tag: merck
Bayer Joins Merck in Fighting Generic Drugs Case
2013-03-13 11:27:45| Chemicals - Topix.net
For more than a decade, drugmakers have battled U.S. Federal Trade Commission accusations that they have colluded to forestall the introduction of dozens of generic medicines, costing buyers as much as $3.5 billion a year.
Tags: case
drugs
generic
fighting
Merck Provides Update on IMPROVE-IT Trial
2013-03-12 13:00:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today said that the Data Safety Monitoring Board (DSMB) of the IMPROVE-IT trial has completed its planned review of study data and recommended that the study continue. The study design calls for the collection of 5,250 clinical endpoints. Merck remains blinded to the actual results of this analysis and to other IMPROVE-IT safety and efficacy data. Language: English Contact HTML: MerckMedia:Kelley Dougherty, 908-423-4291Skip Irvine, 267-305-5397orInvestors:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: update
trial
merck
update merck
Serious side effects seen with failed Merck niacin drug: study
2013-03-09 23:39:43| Biotech - Topix.net
Unexpected serious side effects arose in a huge study of a Merck & Co long-acting niacin drug aimed at raising good HDL cholesterol, according to data released on Saturday, possibly adding a final nail to the coffin of niacin therapy for heart patients.
Merck research head Kim leaving drugmaker; former executive at Merck, Amgen to take over
2013-03-07 22:43:29| Biotech - Topix.net
The world's third-biggest drugmaker by revenue says Dr. Roger Perlmutter, a former research executive at Merck and Amgen Inc., will begin running Merck Research Laboratories on April 15.
Merck Announces Appointment of Roger M. Perlmutter, M.D., Ph.D., As President of Merck Research Laboratories; Peter S. Kim, Ph.D., to Retire
2013-03-07 13:30:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the appointment of Roger M. Perlmutter, M.D., Ph.D., as executive vice president and president of Merck Research Laboratories (MRL), effective April 15. Dr. Perlmutter will succeed Peter S. Kim, Ph.D., who has served in the role since 2003. To ensure a seamless transition, Dr. Perlmutter and Dr. Kim will work closely together for an initial period, after which Dr. Language: English Contact HTML: MerckMedia Contacts:Steven Cragle, 908-423-3461orInvestor Contacts:Alex Kelly, 908-423-5185 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Sites : [122] [123] [124] [125] [126] [127] [128] [129] [130] [131] [132] [133] [134] [135] [136] [137] [138] next »